Cargando…
Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia
The treatment of chronic myeloid leukemia (CML), a disease caused by t(9;22)(q34;q11) reciprocal translocation, has advanced largely through the use of targeted tyrosine kinase inhibitors (TKIs). To identify molecular differences that might distinguish TKI responders from non-responders, we performe...
Autores principales: | Zhang, Weilong, Yang, Beibei, Weng, Linqian, Li, Jiangtao, Bai, Jiefei, Wang, Ting, Wang, Jingwen, Ye, Jin, Jing, Hongmei, Jiao, Yuchen, Chen, Xixi, Liu, Hui, Zeng, Yi-Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803567/ https://www.ncbi.nlm.nih.gov/pubmed/33226961 http://dx.doi.org/10.18632/aging.104136 |
Ejemplares similares
-
Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014) -
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016) -
Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011) -
Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib
por: Chen, Xiaowen, et al.
Publicado: (2020) -
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)